Clinical Trial Update: Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pelabresib added to ruxolitinib in Japanese adults with myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pelabresib (pelabresib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Status: NOT_YET_RECRUITING